Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Coherus BioSciences, Inc. (NASDAQ: CHRS).

Full DD Report for CHRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CHRS)

Blog Exposure - Xenon Announced Presentation of Positive XEN1101 TMS Pharmacodynamic Phase-1 Data at 14th Eilat Conference
Stock Monitor: Coherus BioSciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 17, 2018 / If you want access to our free research report on Xenon Pharma Inc. (NASDAQ: XENE ), all you need to do is sign up now by clicking the following link www.active-investors.com/registrati...
Source: ACCESSWIRE IA
Date: May, 17 2018 07:10
Your Daily Pharma Scoop: Galectin Phase 3 Trial, Acer NDA, Chiasma SPA Amendments
Analysis focus: GALT Galectic (GALT) was our focus ticker in one of the articles in the NASH series we did in February. There, we discussed what makes Galectin stand out among the NASH companies. First, it is not a one-trick pony and has a diverse pipeline outside NASH. Second, unlike Genf...
Source: SeekingAlpha
Date: May, 15 2018 10:00
FDA accepts Coherus Bio's refiled application for Neulasta biosimilar, action date November 3
The FDA accepts for review Coherus BioSciences' ( CHRS -0.6% ) resubmitted marketing application seeking approval for CHS-1701, a biosimilar of Amgen's Neulasta (pegfilgrastim). The agency's action date in November 3. More news on: Coherus BioSciences, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 14 2018 12:57
U.S. Food and Drug Administration Accepts and Acknowledges Coherus BioSciences Biologics License Application of CHS-1701 (Pegfilgrastim Biosimilar Candidate) for Review
REDWOOD CITY, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ:CHRS), today announced the U.S. Food and Drug Administration (FDA) has accepted and acknowledged for review the re-submission of the biologics license application (BLA) for CHS-1701, a pegfilgrastim (Ne...
Source: GlobeNewswire
Date: May, 14 2018 12:39
Your Daily Pharma Scoop: Our Watchlist Pick ARMO Acquired, Ziopharma Low Cash, Coherus PDUFA Date
Analysis focus: ARMO Eli Lilly (NYSE: LLY ) has agreed to acquire ARMO BioSciences for $1.6bn ($50/share) in cash. This is almost a 40% premium to ARMO’s previous closing price of $29.82. It is currently trading at $49.80. The transaction will close this quarter, helping Lilly bol...
Source: SeekingAlpha
Date: May, 11 2018 10:00
Coherus BioSciences' (CHRS) CEO Dennis Lanfear on Q1 2018 Results - Earnings Call Transcript
Coherus BioSciences Inc. (CHRS) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET Executives Patrick O’Brien – Senior Vice President-Investor Relations Denny Lanfear – President, Chief Executive Officer and Chairman Jean Viret – Chief Financial ...
Source: SeekingAlpha
Date: May, 10 2018 21:08
Protalix: Valuable, Misunderstood, And Deeply Mispriced
Editor's note: Seeking Alpha is proud to welcome The Sensible Steward as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » Abo...
Source: SeekingAlpha
Date: May, 10 2018 17:17
Coherus end Q1 with $95M in quick assets, expects FDA action date on Neulasta biosimilar by November
Coherus BioSciences (NASDAQ: CHRS ) Q1 net loss was ($44.3M). Cash and equivalents plus short-term investments totaled $95.1M at quarter-end. More news on: Coherus BioSciences, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: May, 10 2018 16:15
Coherus BioSciences Reports Corporate Highlights and First Quarter 2018 Financial Results
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2018.   First Quarter 2018 Corporate Highlights Include: Oncology therapeutic ...
Source: GlobeNewswire
Date: May, 10 2018 16:01
Coherus BioSciences Appoints Samuel Nussbaum, M.D. to Board of Directors
REDWOOD CITY, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced the appointment of Samuel Nussbaum, M.D. to its Board of Directors.   “We are thrilled to have a health care policy and payer expert of Dr. Nussbaum’s s...
Source: GlobeNewswire
Date: May, 10 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1816.2015.9516.2015.70422,858
2018-05-1716.2015.9516.2015.70422,858
2017-06-1214.1515.72515.87514.057,378,129
2017-06-0922.9520.6523.159120.55773,891
2017-06-0820.6522.7023.2420.651,061,591

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2445,086203,04122.2054Cover
2018-05-23190,491613,47931.0509Cover
2018-05-22347,057614,86356.4446Short
2018-05-2133,23177,51742.8693Short
2018-05-1835,85676,29446.9971Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CHRS.


About Coherus BioSciences, Inc. (NASDAQ: CHRS)

Logo for Coherus BioSciences, Inc. (NASDAQ: CHRS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CHRS)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 13 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: CHRS)

      Daily Technical Chart for (NASDAQ: CHRS)


      Stay tuned for daily updates and more on (NASDAQ: CHRS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CHRS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CHRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CHRS and does not buy, sell, or trade any shares of CHRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/